It is an autosomal dominant disorder with variable expression and penetrance with a prevalence of about 0.2% in general population [1] and is associated with 16 nuclear and 3 mitochondrial gene mutations. Most of these genes encode for both sarcomeric and non sarcomeric proteins as listed in Table 1 . It is further classifi ed into several sub types as asymmetric septal hypertrophy (with and without obstruction), ventricular hypertrophy, hypertrophy of left ventricular posterior wall and apical hypertrophy based on their morphology and BACKGROUND: Cardiomyopathies are a heterogeneous group of heart muscle disorders and are classifi ed as 1) Hypertrophic Cardiomyopathy (HCM) 2) Dilated cardiomyopathy (DCM) 3) Restrictive cardiomyopathy (RCM) and 4) Arrhythmogenic right ventricular dysplasia (ARVD) as per WHO classifi cation, of which HCM and DCM are common. HCM is a complex but relatively common form of inherited heart muscle disease with prevalence of 1 in 500 individuals and is commonly associated with sarcomeric gene mutations. Cardiac muscle troponin I (TNNI-3) is one such sarcomeric protein and is a subunit of the thin fi lament-associated troponin-tropomyosin complex involved in calcium regulation of skeletal and cardiac muscle contraction. Mutations in this gene were found to be associated with a history of sudden cardiac death in HCM patients. AIM: Therefore the present study aims to identify for mutations associated with troponin I gene in a set of HCM patients from Indian population.
MATERIALS AND METHODS:
Mutational analyses of 92 HCM cases were carried out following PCR based SSCP analysis.
RESULTS:
The study revealed band pattern variation in 3 cases from a group of 92 HCM patients. This band pattern variation, on sequencing revealed base changes, one at nt 2560 with G>T transversion in exon-5 region with a wobble and others at nt 2479 and nt 2478 with G>C and C>G transversions in the intronic region upstream of the exon 5 on sequencing. Further analysis showed that one of the probands showed apical form of hypertrophy, two others showing asymmetric septal hypertrophy. Two of these probands showed family history of the condition. CONCLUSIONS: Hence, the study supports earlier reports of involvement of TNNI-3 in the causation of apical and asymmetrical forms of hypertrophy.
Key words: Genetic variation, hypertrophic cardiomyopathy, sudden cardiac death, troponin-I Myosin binding protein C (MYBPC3) 11p11
Cardiac troponin T (TNNT2) 1q32
Cardiac troponin I (TNNI3) 19q13
Cardiac troponin C (TNNC1) 3p21-14
Alpha tropomyosin (TPM1) 15q22.1
Essential myosin light chain (MYL3) 3q21
Regulatory myosin light chain (MYL2) 12q23-q24
Cardiac actin (ACTC) 15q14
Telethonin 17q12 Alpha-myosin heavy chain 14q12
Non sarcomeric genes
AMP-activated protein kinase (PRKAG2) 7q36
Cardiac muscle LIM protein (CLP) 11p15.1
Cardiac myosin light-peptide kinase 20q13.3
Caveolin 3 3p25
Mitochondrial genes their association with different gene mutations.
One of the sarcomeric genes, Cardiac muscle troponin I (TNNI-3) is a basic globular protein, expressed only in the heart. [2] It is a subunit of the thin fi lament-associated troponin-tropomyosin complex involved in calcium regulation of skeletal and cardiac muscle contraction.
Eight coding exons of TNNI-3 code for a polypeptide of 210 amino acids [3, 4] and mutations in this gene account for a total of 5% HCM cases, with a history of sudden cardiac death and poor prognosis. Hence this gene was screened for mutations in a group of clinically wellcharacterized HCM patients.
Materials and Methods
A total of 92 cases confi rmed for HCM based on medical history, physical examination, electrocardiogram and echocardiogram fi ndings were included in the study.
These cases were referred to the cardiology units of CARE hospitals, Hyderabad and KEM Hospital, Mumbai.
In addition to these cases, 100 voluntary blood donors with no history/family history of any cardiac disorders were included as controls in the study. Informed consent was obtained from all the participating individuals along with Institutional ethics committee clearance.
Isolation of total genomic DNA from whole blood [5] of patients and controls was carried out followed by PCR based SSCP analysis. [6] Primer sequences for PCR were obtained based on available database of Seidman. Amplifi ed products were mixed with equal volumes of formamide loading buffer (formamide 0.9 g/ml, 10 mM NaOH, 11 mM EDTA), denatured at 95°C for 10 min and quenched on ice for 5 min prior to loading.
8 µl of diluted samples were loaded onto 10% nondenaturing polyacrylamide gel and placed in Consortium electrophoresis unit at 150 Volts and 15 mA current.
After electrophoresis, band pattern was visualized by silver staining according to the protocol of Orita et al. [6] On a stained SSCP gel, mobility shift was recognized as an aberrant band pattern compared to the control sample's band pattern. PCR products showing an aberrant band pattern on SSCP gels were later purifi ed and commercially sequenced on a 373 DNA analyzer;
Macrogen (Korea) for the detection of either SNPs and/or mutations.
Results and Discussion
PCR based SSCP analysis [ Figure 1A Six mutations have been originally described in troponin-I, of which, 5 were missense mutations and one deletion with no disruption of the reading frame.
[8]
Mutations in troponin I gene have been considered as an infrequent cause of HCM although more mutations have recently been reported. [9, 10] Unusual patterns of hypertrophy, including a predominant apical involvement have been associated with troponin I defects. [9, 11] Based on the morphologic pattern of disease, troponin I mutations may be more prevalent in populations with a high incidence of apical HCM, as reported in Japan. [8] Therefore the present finding further supports the involvement of multiple base changes in TNNI-3 in the pathogenesis of apical and asymmetrical septal forms of HCM.
Troponin I, a sub unit of troponin complex exerts a modulator infl uence on the calcium-dependent actinmyosin interaction. The region in which the variations are found in the present study is between the sites interacting with Tn T. Signifi cance of variations in this region in the pathogenesis of the condition needs to be studied by in silico analysis.
Codon bias, the preference for some of the synonymous codons encoding the same amino acid exists in the expression of the genes across organisms. The synonymous changes may exert an effect on the expression by codon-anticodon interaction during translation, which may have effect on translational effi ciency. [12] However this needs to be confi rmed by functional studies.
Base changes in any of the consensus nucleotides of an intron involved in spliceosome complexes other than the required GT and AG pairs can have a regulatory effect on RNA processing, as reported in beta thalassemia.
[13]
The base changes observed in present study (26 bases upstream of intron-exon junction) fall near the region involved in secondary lariat structure formation required for splicing. Since the base changes observed in the patients (FHC 52, 139, 145) were not found in any of the 100 controls screened, it can be suspected that disruption of spliceosome formation may be involved in disease pathogenesis in these individuals. This needs to be further confi rmed by Insilico/invitro studies. ) .
Conclusion

